Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR LS vs INH
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.
FDA: Treatment of postoperative inflammation in patients who have undergone cataract surgery,Off-label: Relief of ocular pain, photophobia, and inflammation associated with corneal abrasion or refractive surgery
First-line treatment and prophylaxis of tuberculosis (TB) caused by Mycobacterium tuberculosis
1 drop in the affected eye(s) four times daily
300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Fast acetylators: 0.5-1.5 hours; slow acetylators: 2-4 hours. Clinically, slow acetylators have higher risk of peripheral neuropathy and hepatotoxicity.
Primarily hepatic via CYP2C9; undergoes glucuronidation and oxidation to inactive metabolites.
Primarily hepatic via N-acetyltransferase 2 (NAT2); also metabolized by cytochrome P450 (CYP2E1) to hepatotoxic metabolites.
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
Renal: 75-95% as unchanged drug and metabolites (including acetylisoniazid, isonicotinic acid). Biliary/fecal: minor (<5%).
Ketorolac is highly protein bound, approximately 99% bound to plasma proteins, primarily albumin.
0-10% (low binding; primarily albumin).
The volume of distribution is approximately 0.12 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
0.6-0.8 L/kg (distributes into total body water, including cerebrospinal fluid and tuberculous cavities).
Ophthalmic bioavailability is approximately 2% of the administered dose due to extensive nasolacrimal drainage and systemic absorption. Oral bioavailability of ketorolac is approximately 80-100%, but this route is not used for ophthalmic formulations.
Oral: ~90%. Intramuscular: ~100%.
No dosage adjustment required for renal impairment
In patients with GFR < 30 m L/min, reduce dose to 200 mg daily or 300 mg three times weekly. For GFR 30-50 m L/min, no adjustment necessary. For GFR < 10 m L/min, consider 150 mg daily or 300 mg twice weekly.
No dosage adjustment required for hepatic impairment but use with caution in severe hepatic disease due to potential for increased systemic exposure
In Child-Pugh class A, no adjustment. In Child-Pugh class B, reduce dose to 200 mg daily. In Child-Pugh class C, use 150 mg daily or avoid if severe hepatic impairment.
Safety and efficacy in pediatric patients below 2 years of age have not been established; for children 2 years and older, same as adult dosing
10-15 mg/kg orally once daily (max 300 mg) for active tuberculosis; for latent tuberculosis, 10-15 mg/kg orally once daily (max 300 mg) or 20-40 mg/kg orally twice weekly (max 900 mg per dose).
No specific dose adjustment recommended; use with caution due to increased incidence of age-related ocular conditions
No specific dose adjustment required, but monitor for hepatotoxicity and peripheral neuropathy, especially in patients with comorbidities or polypharmacy.
None
Severe and sometimes fatal hepatitis (especially in patients >35 years, daily alcohol users, and those with pre-existing liver disease); monitor hepatic function closely.
Increased risk of bleeding and bleeding-related adverse events due to platelet inhibition,May prolong bleeding time,Cross-sensitivity with aspirin and other NSAIDs,Caution in patients with prior history of corneal epithelial defects or ocular surgery,Not for intraocular injection
Hepatotoxicity (monitor LFTs, discontinue if signs of hepatitis),Peripheral neuropathy (pyridoxine prophylaxis recommended),CNS effects (seizures, psychosis; avoid in active CNS disease),Lupus-like syndrome,Drug interactions (e.g., carbamazepine, phenytoin)
Hypersensitivity to ketorolac tromethamine or any component of the formulation,Patients with active peptic ulcer disease, recent GI bleeding, or perforation,Patients with advanced renal disease or at risk for renal failure,Patients with known history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
Acute liver disease,History of INH-induced hepatotoxicity,Previous severe adverse reaction (e.g., drug fever, arthritis)
No known food interactions for ophthalmic ketorolac. However, maintain good hydration and nutrition to support corneal healing.
Foods high in tyramine (e.g., aged cheese, cured meats, soy products) may rarely cause hypertensive crisis in patients also taking MAOIs, though interaction is less significant with INH alone. High-fat meals may delay absorption, so avoid fatty foods near dosing time. No specific dietary restrictions beyond taking on empty stomach.
Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during organogenesis resulted in increased embryofetal mortality, delayed ossification, and increased incidence of skeletal abnormalities at doses less than the maximum recommended human ophthalmic dose. However, systemic exposure following ocular administration is very low. NSAIDs are generally avoided during pregnancy, especially in the third trimester, due to the risk of premature closure of the ductus arteriosus and oligohydramnios. The risk is considered low for ophthalmic use but should be used only if clearly needed.
INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential for hepatotoxicity and peripheral neuropathy, and possibly increased risk of neonatal hemorrhage due to vitamin K deficiency.
It is not known whether ketorolac is excreted in human milk after ophthalmic administration. Systemic levels are low, and following oral administration, ketorolac is excreted in breast milk at low concentrations (M/P ratio approximately 0.37). Due to the potential for adverse effects on the nursing infant, caution should be exercised. The low systemic absorption likely poses minimal risk.
INH is excreted into breast milk in low concentrations (M/P ratio approximately 1.6). Breastfeeding is generally considered safe, but monitor infant for signs of peripheral neuropathy or liver toxicity. The American Academy of Pediatrics considers INH compatible with breastfeeding.
No dosing adjustments are necessary for ophthalmic use during pregnancy due to negligible systemic absorption. Standard dosing (1 drop in the affected eye(s) four times daily) is recommended. Systemic NSAIDs may require dose adjustment due to increased volume of distribution and renal changes, but this does not apply to topical ocular ketorolac.
No dose adjustment is routinely required for pregnancy. However, due to increased clearance (30-50% higher), some experts recommend monitoring serum INH levels and adjusting dose to maintain therapeutic levels. Pyridoxine supplementation (25-50 mg/day) is recommended to prevent peripheral neuropathy.
ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and photophobia following corneal refractive surgery. Use with caution in patients with known bleeding tendencies or those on anticoagulants due to increased risk of ocular bleeding. Avoid concurrent use with other NSAIDs or steroids to minimize corneal adverse effects. Monitor for corneal epithelial breakdown or delayed healing.
Administer on an empty stomach (1 hour before or 2 hours after meals) to maximize absorption. Monitor liver function tests (ALT, AST) at baseline and monthly during therapy. Pyridoxine (vitamin B6) 25-50 mg/day should be co-administered to prevent peripheral neuropathy. Hepatotoxicity risk increases with age, alcohol use, and concurrent use of other hepatotoxic drugs. Slow acetylators are more prone to toxicity. Patients with liver disease require careful monitoring and dose adjustment.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Use only in the affected eye(s) as prescribed; do not use for longer than directed.,Temporary stinging or burning may occur upon instillation.,Report any persistent pain, redness, or visual changes to your doctor immediately.,Avoid driving or operating machinery if vision is blurred after use.
Take on an empty stomach with a full glass of water.,Do not drink alcohol while taking this medication due to increased risk of liver damage.,Report immediately any signs of liver problems: dark urine, yellowing of skin or eyes, persistent nausea, or abdominal pain.,Take vitamin B6 as prescribed to prevent numbness or tingling in hands and feet.,Complete full course of therapy even if you feel better to prevent resistance.,Avoid antacids within 1 hour of taking this medication as they may reduce absorption.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR LS vs INH, answered by our medical review team.
ACULAR LS is a NSAID Ophthalmic that works by Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.. INH is a Antitubercular Agent that works by INH inhibits Inh A, an enoyl-acyl carrier protein reductase involved in mycolic acid synthesis, essential for the mycobacterial cell wall. It also disrupts NAD and NADH metabolism via the Kat G-activated isonicotinoyl-NAD adduct.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR LS and INH depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR LS is: 1 drop in the affected eye(s) four times daily. The standard adult dose of INH is: 300 mg orally once daily (or 15 mg/kg orally once daily, up to 300 mg total) for active tuberculosis; for latent tuberculosis, 300 mg orally once daily or 900 mg orally twice weekly under directly observed therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR LS and INH in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR LS is classified as Category C. Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during org. INH is classified as Category C. INH (isoniazid) is not known to be a major teratogen. In first trimester, risk of malformations is not significantly increased. In second and third trimesters, there is a potential. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.